We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this free, full length talk
Topics Covered
- The self-amplifying RNA vaccine technology
- Current stage of the clinical trial
- Next steps in the clinical trial
- The future of the vaccine
Biography
Dr Katrina Pollock is a Senior Clinical Research Fellow in Vaccinology and Honorary Consultant at Imperial College London. She is Chief Investigator for the Imperial COVID-19 RNA vaccine trials and Principle Investigator for the Oxford COVID-19 vaccine trials. She read medicine as an undergraduate at Newnham College, University of Cambridge, and then at Imperial College School of Medicine before completing speciality training as a clinician scientist in genitourinary and HIV medicine. She now leads a series of experimental medicine, early phase, and first-in-human trials for the development of novel vaccines against a broad variety of pathogens including HIV, chlamydia, Ebola, malaria, and most recently SARS-CoV-2 infection.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Pollock, K. (2020, October 25). Imperial College London’s saRNA Vaccine - COVAC1 [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 30, 2023, from https://hstalks.com/bs/4442/.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Katrina Pollock has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Playlist: Interviews on Covid-19
Transcript
Please wait while the transcript is being prepared...
0:00
Interviewer: Doctor Pollock, thank you very much for taking the time today for
this interview on Imperial College London's RNA vaccine.
Could you please give an overview on the molecular basis of the vaccine,
and therefore, how it works?
. Pollock: Thank you for inviting me to talk about
the imperial College COVID-19 vaccine program today.
It's an honour to be here.
I'd like to tell you about the design of the vaccine first of all.
We're using a molecular vaccine which adopts a self-amplifying RNA design.
What that means is that we're using a molecule of RNA,
which once it enters into the cell,
can be amplified and increase the potency of the vaccine.
The way that works is quite complex,
but I can break it down into several different steps.
This is part of a wider global push
to really improve the work that's previously been done in
molecular vaccinology and really test the boundaries of
this technology in order to deliver new vaccines that can respond rapidly to pandemics.
The way that self-amplifying RNA works is that once inside the cell,
it encodes for a protein replicon which is derived from an alphavirus.
That allows the vaccine itself to be replicated,
so you get more copies than just the few that you initially received from the vaccine.
At the same time, within the vaccine,